TQB2029

· Chia Tai Tianqing Pharmaceutical Group; Nanjing Shunxin Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TQB2029, covering 2024-12-06 to 2024-12-06. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma [Phase 1]